Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2018 2
2019 7
2020 6
2021 2
2022 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Dumas PY, Raffoux E, Bérard E, Bertoli S, Hospital MA, Heiblig M, Desbrosses Y, Bonmati C, Pautas C, Lambert J, Orvain C, Banos A, Pasquier F, Peterlin P, Marchand T, Uzunov M, Frayfer J, Turlure P, Cluzeau T, Jourdan E, Himberlin C, Tavernier E, Villate A, Haiat S, Chretien ML, Carre M, Chantepie S, Vaida I, Wemeau M, Chebrek S, Guillerm G, Guièze R, Debarri H, Gehlkopf E, Laribi K, Marcais A, Santagostino A, Béné MC, Mineur A, Pigneux A, Dombret H, Récher C. Dumas PY, et al. Among authors: desbrosses y. Leukemia. 2023 Jan;37(1):91-101. doi: 10.1038/s41375-022-01742-7. Epub 2022 Nov 14. Leukemia. 2023. PMID: 36376378 Free article.
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.
Orvain C, Bertoli S, Peterlin P, Desbrosses Y, Dumas PY, Iat A, Hospital MA, Carre M, Tavernier E, Riou J, Bouvier A, Bidet A, Tondeur S, Renosi F, Mozziconacci MJ, Flandrin-Gresta P, Dadone-Montaudié B, Delabesse E, Pigneux A, Hunault-Berger M, Recher C. Orvain C, et al. Among authors: desbrosses y. Leukemia. 2024 Sep;38(9):1949-1957. doi: 10.1038/s41375-024-02335-2. Epub 2024 Jul 17. Leukemia. 2024. PMID: 39020060 Free PMC article.
[Related donors follow-up: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Polomeni A, Culat-Farhat M, Desbrosses Y, Andrianne C, Ainaoui M, Baillie E, Bancillon N, de Bentzmann N, Bouya S, Duteil E, Fraysse C, Issarni D, Ruscassie A, Sauze S, Thibert JB, Yakoub-Agha I, Faucher C. Polomeni A, et al. Among authors: desbrosses y. Bull Cancer. 2020 Jan;107(1S):S94-S103. doi: 10.1016/j.bulcan.2019.02.006. Epub 2019 Apr 18. Bull Cancer. 2020. PMID: 31006487 French.
[Oral complications following allogeneic hematopoietic cell transplantation: Recommendations of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)].
Souchet L, Ahmad I, Hamzy F, Ceballos P, Desbrosses Y, Ravinet A, Turlure P, Villate A, Vigarios E, Borel C, Yakoub-Agha I, Guillaume T. Souchet L, et al. Among authors: desbrosses y. Bull Cancer. 2020 Dec;107(12S):S122-S129. doi: 10.1016/j.bulcan.2020.03.017. Epub 2020 Jun 10. Bull Cancer. 2020. PMID: 32532421 Review. French.
[Graft reinjection: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Tarillon S, Andrianne C, Balcaen S, Bole S, Genty C, Godin S, Lemarchand E, Mouchebeuf J, Mussot I, Wallart A, Alsuliman T, Desbrosses Y, El Cheikh J, Guerout-Verite MA, De Vos J, Tardieu L, Yakoub-Agha I, Porcheron S. Tarillon S, et al. Among authors: desbrosses y. Bull Cancer. 2019 Jan;106(1S):S83-S91. doi: 10.1016/j.bulcan.2018.11.001. Epub 2018 Dec 7. Bull Cancer. 2019. PMID: 30528618 French.
[Transfusion in autologous and allogenic hematopoietic stem cell transplant: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Giraud C, Thibert JB, Desbrosses Y, Debiol B, Alsuliman T, Bardiaux L, Garban F, Huynh TNP, Samsonova O, Yakoub-Agha I, Bruno B. Giraud C, et al. Among authors: desbrosses y. Bull Cancer. 2019 Jan;106(1S):S52-S58. doi: 10.1016/j.bulcan.2018.08.016. Epub 2019 Jan 18. Bull Cancer. 2019. PMID: 30665669 French.
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia.
Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S; French AML Intergroup ALFA/FILO. Fodil S, et al. Among authors: desbrosses y. Leuk Lymphoma. 2021 Jul;62(7):1756-1760. doi: 10.1080/10428194.2021.1881505. Epub 2021 Feb 17. Leuk Lymphoma. 2021. PMID: 33596765 No abstract available.
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, Haderbache R, Roussel X, Desbrosses Y, Daguindau E, Renosi F, Roumier C, Bouquet L, Biichle S, Guiot M, Seffar E, Caillot D, Depil S, Robinet E, Salma Y, Deconinck E, Deschamps M, Ferrand C. Trad R, et al. Among authors: desbrosses y. J Immunother Cancer. 2022 Jul;10(7):e004222. doi: 10.1136/jitc-2021-004222. J Immunother Cancer. 2022. PMID: 35803613 Free PMC article.
21 results